The present invention relates to a method for determining an anti-RA33 antibody IgG and a reagent device, which belongs to the technical field of biological detection.
RA (Rheumatoid Arthritis) is a most common systemic autoimmune disease, which is mainly represented as chronic, symmetrical, arthritis erosive synovitis; wherein the disease is mostly progressive; and about one third of the patients may be crippled if the disease may not be treated timely. Therefore, early diagnosis and early treatment are the keys to treat Rheumatoid Arthritis. The diagnostic criteria amended by ACR (American College of Rheumatology) in 1987 is based on clinical manifestation; and the specificity of rheumatoid factors (RF) which serves as the unique diagnostic criteria is poor. Therefore, rheumatologists are all committed to search biological markers for the early diagnosis of RA (Rheumatoid Arthritis) and have gained certain achievements.
An anti-RA33 antibody was reported by Hassfeld et al. for the first time in 1989; as the antibody is a more specific antibody for diagnosing RA (Rheumatoid Arthritis) and reacts with nucleic acid protein with a molecular weight of 33 KD, the antibody is accordingly named as anti-RA33 antibody. Target antigen of the anti-RA33 antibody is nucleic acid binding protein with a molecular weight of 33 KD, which is consistent with A2 protein in hnRNP; and the antigen is from HeLa cell or Ehrilich cell. IBT (Immunoblotting Test) is adopted as a detection method. At the same time of detecting the anti-RA33 antibody in 1992, Hassfeld found that partial RA patients also had an anti-36 KD nucleic acid protein antibody; moreover, the anti-36 KD nucleic acid protein antibody is irrelevant to an anti-proliferating cell nuclear antigen antibody (Anti-PCNA Antibody). The anti-RA33 antibody and an anti-RA36 antibody always appear at the same time; moreover, two characteristic bands formed at positions of 33 KD and 36 KD which exist at the same time during the IBT (Immunoblotting Test) has specificity on diagnosing RA. In various indexes of early RA diagnosis, the specificity of the anti-RA33 antibody is highest; the positive rate of the antibody in RA is 35.8 percent and the antibody appears in early RA in particular. The succession of the anti-RA33 antibody is irrelevant to the disease and the drugs used.
In addition, the anti-RA33 antibody except exists in the bodies of partial RA patients, the anti-RA33 antibody also exists in about 20 percent of SLE (Systemic Lupus Erythematosus) patients and 40 percent to 60 percent of MCTD (Mixed Connective Tissue Disease) patients. However, it is reported in literatures that the anti-RA33 antibody in SLE patients and MCTD patients always exist at the same time with another two autoantibodies, which include anti-U1-RNP antibody and anti-Sm antibody; therefore, SLE (Systemic Lupus Erythematosus) and MCTD (Mixed Connective Tissue Disease) may be excluded by examining the anti-U1-RNP antibody and the anti-Sm antibody at the same time.
IBT (Immunoblotting Test) is earliest and most frequently used for detecting the anti-RA33 antibody; in addition, ELISA (Enzyme Linked Immunosorbent Assay) may also be used for detecting; however, these method both have disadvantages.
IBT (Immunoblotting Test) was reported by Hassfeld et al. for the first time in 1989 to detect the anti-RA33 antibody in serum of RA patients. IBT (Immunoblotting Test) is hybridization
Technique which combines high resolution gel electrophoresis technique with an immunochemistry analysis technique. IBT (Immunoblotting Test), which has the advantages of large analysis capacity, high sensitivity and strong specificity, etc, is a most common method for detecting protein characteristics, expression and distribution, such as qualitative and quantitative detection of tissue antigens, quantity determination of peptide molecules as well as virus antibody or antigen detection, and the like. The advantages of IBT (Immunoblotting Test) are as follows:
Compared with other biological detection or immunological detection, application of ELISA (Enzyme Linked Immunosorbent Assay) is limited due to a pluralities of disadvantages thereof on detection method, technique and tool or product, which mainly comprise the several aspects as follows:
In order to solve the defects of the existing anti-RA33 antibody IgG analysis and detection method, the present invention provides a new detection method, a reagent device and ancillary reagents. The method is based on an ELISA (Enzyme Linked Immunosorbent Assay) technique to search a set of simpler, more accurate and effective method and reagents to implement quantitative determination so as to meet the demands of clinical diagnosis.
The method is based on an ELISA (Enzyme Linked Immunosorbent Assay) principle to implement immunological detection on the anti-RA33 antibody IgG, and relates to an independent, single portion and one-off analysis method, a reagent device and ancillary reagents used for detecting the anti-RA33 antibody IgG by means of ELISA (Enzyme Linked Immunosorbent Assay), wherein a plurality of reagents needed for detecting the anti-RA33 antibody IgG by means of ELISA (Enzyme Linked Immunosorbent Assay) may be held on one analytical device; relevant immunological detections may be conveniently carried out in accordance with use demands of the detection items through the method, thus providing better basis for clinical application.
The present invention provides a method for determining an anti-RA33 antibody IgG, wherein the method is implemented by a to a kit consisting of an ELISA (Enzyme-linked Immunosorbent Assay) analytical reagent device and ancillary reagents, wherein the analytical reagent device comprises a substrate provided with 8 holes, and a handle located at one end of the substrate; various specific reagent solutions between the holes of the reagent device are filled and aspirated by a specific analytical instrument to make samples react with the reagents, then a numerical value of solution color after reaction is measured, and finally the measured numerical value is processed to obtain a detection result.
According to the method for determining the anti-RA33 antibody IgG, an anti-RA33 antibody IgG to be detected in a sample to be detected is reacted with a recombinant RA33 antigen to form a first immune complex; the first immune complex is reacted with a second antibody labeled by enzyme to form a second immune complex; chromogenic contrast analysis is carried out between the second immune complex formed by reaction and a chromogenic substrate so as to obtain contents of the anti-RA33 antibody IgG to be detected.
According to the method for determining the anti-RA33 antibody IgG, the second antibody is an anti-human IgG antibody labeled by HRP (Horse Radish Peroxidase).
The present invention provides a reagent device for determining an anti-RA33 antibody IgG, wherein the reagent device is provided with a substrate with 8 holes, a handle located at one end of the substrate, an analytical reagent device used for detecting the anti-RA33 antibody IgG by means of ELISA (Enzyme-linked Immunosorbent Assay) as well as components of corresponding quantities such as ancillary reagent calibrators, quality control materials and buffer washing solutions.
According to the reagent device for determining an anti-RA33 antibody IgG, a label of a detection reagent bar code is stuck on the handle located at one end of the substrate; numerical values of the bar code comprises such information as detection item code, detection reagent batch number, reagent validity, qualitative adjusted value/quantitative assay standard curve parameters, ELASA (Enzyme Linked Immunosorbent Assay) reaction type as well as serial numbers of reagents and analytical device corresponding to each detection.
According to the reagent device for determining an anti-RA33 antibody IgG, the holes comprises a reaction hole, a sample hole, a dilution hole and five reagent holes, wherein,
According to the reagent device for determining an anti-RA33 antibody IgG, the reagents required for detecting the anti-RA33 antibody IgG by means of ELASA (Enzyme Linked Immunosorbent Assay) and held in the reagent holes comprise immune reaction inhibitor/neutralizer/blocker/absorbent, enzyme-conjugate solution, chromogenic substrate solution, chromogenic stop solution, reaction enhancer/accelerator and sample dilution solution required by the ELASA (Enzyme Linked Immunosorbent Assay) for detecting the anti-RA33 antibody IgG.
According to the reagent device for determining an anti-RA33 antibody IgG, the section shapes of the sample hole, the reaction hole, the dilution hole and the reagent holes comprise flat shape, V shape or U shape, or any combination between flat shape, V shape and U shape.
The method for determining an anti-RA33 antibody IgG comprises the steps as follows:
The analytical reagent device relates to an independent, single purpose and one-off ELISA (Enzyme-linked Immunosorbent Assay) analytical reagent device for determining the anti-RA33 antibody IgG, and specially used for a specific analytical instrument.
According to the method of the present invention for determining the anti-RA33 antibody IgG and ancillary reagents by means of ELISA (Enzyme-linked Immunosorbent Assay), the analytical
Reagent device for implementing detection of the anti-RA33 antibody IgG relates to an independent, single purpose and one-off ELISA (Enzyme-linked Immunosorbent Assay) analytical reagent device specially used for a specific analytical instrument.
The method and the device of the present invention for determining the anti-RA33 antibody IgG inherit such characteristics of other detection methods as strong specificity, high sensitivity, good accuracy, low cost, low use requirement, simple and convenient operation, short detection result obtaining time and broad application, and solve a plurality of defects of other detection methods, which comprise the several aspects as follows specifically:
1 refers to the sample hole; 2, 3, 4, 5 and 6 refer to the reagent holes; 7 refers to the reaction hole, 8 refers to the dilution hole; 9 refers to the handle; 10 refers to the sealing film; 11 refers to the substrate and 90 refers to the label.
The following descriptions are further described by reference to the specific determination device and implementation steps of the determination method and the reagent device of the present invention, to make the public better understand the technical scheme of the present invention, rather than to limit the technical scheme. In fact, improvement on the steps of the method as well as increasing and decreasing, replacement and improvement on the structures of the corresponding reagent devices shall all fall within the protection scope of the present invention.
The present invention relates to a set of simpler, more accurate and effective method based on ELISA (Enzyme-linked Immunosorbent Assay) technique, and adopts a basic principle of indirect ELISA (Enzyme-linked Immunosorbent Assay). A recombinant RA33 antigen is absorbed on a solid phase; a specific antibody in diluted human serum is combined with the antigen by incubation, and then the antibody not combined with the solid phase is removed by washing; anti-human IgG enzyme conjugate labeled by HRP (Horse Radish Peroxidase) is added for incubation. The enzyme conjugate which is not combined is removed, and enzyme chromogenic substrate is added. A color generated is proportional to the concentrate of the specific antibody in the sample to be detected. The method mainly implements the immunological detection of the anti-RA33 antibody IgG through the analytical reagent device and the ancillary reagents used for ELISA (Enzyme-linked Immunosorbent Assay). Judgment may be made quickly and accurately for the demand of clinical diagnosis by ELISA (Enzyme-linked Immunosorbent Assay) as well as application of the analytical reagent device and the reagents of the specific analytical instrument. The detailed structure of the analytical device thereof is as follows:
As illustrated in
stuck on the handle. In the example embodiment, the label numbers 2, 3, 4, 5 and 6 refer to the reagent holes; when in use, the reagent holes with the label numbers 2, 3, 4, 5 and 6 have held the reagents required by the detection; moreover, an opening edge of the reaction hole may be square or round and the bottom surface of the reaction hole is a ‘V’-shaped groove; the opening of the reaction hole after holding the reagent or being vacant is sealed by a sealing film 10; the label number 8 refers to the dilution hole which is used for diluting the samples and is not covered by a sealing film.
Other reagents in a kit outside an analytical reagent device comprise: calibrators, quality control materials, buffer washing solution, cleaning solution, disinfectant and distilled water or deionized water.
The hole 1 is used as a vessel for holding the sample to be detected; when in use, a solution sample is added for use during detection; the hole 2 is used as an empty hole and the opening of the hole is sealed by a sealing film for standby during detection; and the hole 3 is used as a reagent vessel and the opening of the hole is sealed by a sealing film for use during detection after a sample dilution reagent is added.
The hole 4 is used as a reagent vessel and the opening of the hole is sealed by a sealing film for use during detection after a stop reagent is added; and the hole 5 is used as a reagent vessel and the opening of the hole is sealed by a sealing film for use during detection after an anti-human IgG antibody labeled by HRP (Horse Radish Peroxidase) is added.
The hole 6 is used as a reagent vessel and the opening of the hole is sealed by a sealing film for use during detection after an enzyme reaction substrate is added.
The hole 7 is used as a coating article hole/reaction vessel/colorimetric hole, which is coated by the recombinant RA33 antigen, served as a reaction vessel and filled with the solution sample to be detected, a detection reagent and a washing solution, and finally added with the enzyme reaction substrate for incubation, and then absorbance determination is carried out.
The hole 8 is used as a sample dilution vessel for use during sample dilution.
The handle 9 is stuck with the bar code 90 of the information of the reagent and the analytical device for determining the anti-RA33 antibody IgG, wherein the car code comprises detection item code, detection reagent batch number, reagent validity, qualitative adjusted value/quantitative assay standard curve parameters, ELASA (Enzyme Linked Immunosorbent Assay) reaction type as well as serial numbers of reagents and analytical devices corresponding to each detection.
A plurality of analytical devices are prepared according to the foregoing methods; in addition, corresponding reagents are prepared, which comprise calibrators, quality control materials, buffer washing solution, cleaning solution, disinfectant and distilled water or deionized water, and the like. In this way, complete kit components for determining the anti-RA33 antibody IgG are formed. The reagent devices for determining the anti-RA33 antibody IgG and the ancillary components are filled into an external packaging box of the kit, thus manufacturing the kit for determining the anti-RA33 antibody IgG.
The full-automatic analyzer comprises an analytical device tray which is matched with the shape of the analytical device, wherein the tray is equipped with 30 positions for placing the analytical devices and used for detection and analysis. In addition, a modular integrated mechanical and electronic structure which may implement automatic sample loading, dilution, incubation, washing and reading process is further included. Each position implements quantitative analysis independently; moreover, more than 200 electronic sensor monitoring instruments are operating to guarantee the accuracy of the result. After the instruments are operating, the analytical device tray may automatically rotate to different positions for implementing the steps of sample loading, dilution, incubation, washing and reading.
After an instrument switch is turned on, the instrument may automatically carry out a series of examinations, so as to prepare for the normal operation of the instrument.
(2) Preparation of examination programs
Prepare corresponding solutions as required, comprising buffer washing solution, cleaning solution, disinfectant and distilled water or deionized water, and fill the solutions into corresponding solution tanks after completing the preparation.
(3) Flushing examination
After starting up, the instrument may enable a heating program to adjust temperature to the temperature to be detected.
(5) Connected with a host machine
The instrument may be connected with the host machine through a RS232 serial port, thus submitting a result obtained by normal work of the instrument to a centralized system for processing.
(6) Detection of anti-RA33 antibody IgG
When a detection program operates completely, click data transmission with the host machine, the instrument may automatically send the result obtained by the normal work to the host machine and handle over to external data processing software to analyze and finally generate a report for consulting.
After the detection is completed, washing circulation shall be enabled before shutdown of the instrument; in this way, residual saline matter from solutions may be avoided from crystallizing in a solution path to prevent the instrument from being damaged or causing invalid detection result; after the washing is completed, the instrument automatically turns off a power supply.
The operating method and program of the example embodiment 3 and the kit of the example embodiment 2 may be used for quantitatively determining the level of the anti-RA33 antibody IgG in human serum.
The anti-RA33 antibody appeared singly is considered as a marker for RA (Rheumatoid Arthritis); however, the sensitivity of diagnosis thereof is depended on crowd to be detected. The anti-RA33 antibody appears independently without relying on RF (Rheumatoid Factors), and the occurrence rate of the anti-RA33 antibody in negative RF (Rheumatoid Arthritis) is about 45 percent; moreover, the anti-RA33 antibody is significantly important to the early diagnosis of RA (Rheumatoid Arthritis). The anti-RA33 antibody may occur in 70 percent of SLE (Systemic Lupus Erythematosus) patients accompanied with EA (Erosive Arthritis); therefore, the anti-RA33 antibody may be served as a predictive index for development of EA (Erosive Arthritis) in SLE (Systemic Lupus Erythematosus). Therefore, we may carry out clinical diagnosis according to the detection result to primarily judge the disease situation of the patient; moreover, the final diagnosis shall be comprehensively considered by giving references to the clinical manifestation or other diagnosis methods/indexes.
The following is analysis on the detection result:
(1) Reference value (reference scope)
The normal reference value: 0-25 AU/mL; a certain quantity of negative samples (with statistical significances) are detected; an average value of the result plus 3 times of standard deviations (that is,
Sample value<20 AU/mL Negative
20 AU/mL<sample value<30 AU/mL Doubtful
Sample value>30 AU/mL Positive
(2) Explanations of the detection result
Result explanation: when the sample value is >30 AU/mL, the concentration of the antibody is increased obviously, whether having got RA (Rheumatoid Arthritis) and EA (Erosive Arthritis) shall be diagnosed by giving reference to the clinical manifestation or other diagnosis methods/indexes; when the sample value is <20 AU/mL, the level of the anti-RA33 antibody of an organism is not increased obviously; when 20 AU/mL<the sample value <30 AU/mL, the sample shall be re-detected; if the value is still doubtful, the sample shall be collected again in 2 to 3 weeks for detection.
The results as follows are obtained by repeatedly detecting the positive and negative quality control serums in the detecting process of the example embodiment 3 and detecting the reproducibility of the results:
According to the present invention, detection of anti-RA33 antibody IgG on a plurality of samples may be automatically carried out through the same analysis process, which simplifies the detection, reduces the cost, shortens the detection time, is hard to generate cross pollution and is easy to carry out detection operation; moreover, the detection specialty is strong, the sensitivity is high, and the accuracy is good.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/CN11/70028 | 1/4/2011 | WO | 00 | 8/5/2013 |